Integrated Advisors Network LLC Increases Stock Holdings in Merck & Co., Inc. (NYSE:MRK)

Integrated Advisors Network LLC lifted its position in Merck & Co., Inc. (NYSE:MRKFree Report) by 1.2% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 48,477 shares of the company’s stock after purchasing an additional 579 shares during the quarter. Integrated Advisors Network LLC’s holdings in Merck & Co., Inc. were worth $5,285,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently modified their holdings of MRK. Sierra Summit Advisors LLC purchased a new position in Merck & Co., Inc. during the fourth quarter worth about $626,000. Scarborough Advisors LLC purchased a new position in Merck & Co., Inc. during the fourth quarter worth about $918,000. WNY Asset Management LLC boosted its stake in Merck & Co., Inc. by 5.8% during the fourth quarter. WNY Asset Management LLC now owns 10,521 shares of the company’s stock worth $1,147,000 after buying an additional 575 shares during the period. Garde Capital Inc. boosted its stake in Merck & Co., Inc. by 25.4% during the fourth quarter. Garde Capital Inc. now owns 7,045 shares of the company’s stock worth $768,000 after buying an additional 1,428 shares during the period. Finally, American Trust boosted its stake in Merck & Co., Inc. by 10.9% during the fourth quarter. American Trust now owns 4,502 shares of the company’s stock worth $491,000 after buying an additional 443 shares during the period. Hedge funds and other institutional investors own 76.07% of the company’s stock.

Merck & Co., Inc. Stock Performance

Shares of MRK traded up $0.11 during mid-day trading on Friday, reaching $129.48. 7,338,462 shares of the company’s stock were exchanged, compared to its average volume of 7,353,206. The company has a debt-to-equity ratio of 0.77, a current ratio of 1.25 and a quick ratio of 0.99. The stock has a market capitalization of $327.95 billion, a PE ratio of 143.87, a price-to-earnings-growth ratio of 2.50 and a beta of 0.39. The business’s fifty day simple moving average is $128.61 and its 200-day simple moving average is $122.34. Merck & Co., Inc. has a 52-week low of $99.14 and a 52-week high of $133.10.

Merck & Co., Inc. (NYSE:MRKGet Free Report) last announced its earnings results on Thursday, April 25th. The company reported $2.07 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.94 by $0.13. The business had revenue of $15.78 billion for the quarter, compared to analyst estimates of $15.21 billion. Merck & Co., Inc. had a net margin of 3.76% and a return on equity of 14.05%. The company’s revenue for the quarter was up 8.9% compared to the same quarter last year. During the same period last year, the firm posted $1.40 earnings per share. On average, equities research analysts expect that Merck & Co., Inc. will post 8.64 earnings per share for the current year.

Merck & Co., Inc. Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Monday, July 8th. Shareholders of record on Monday, June 17th will be paid a $0.77 dividend. The ex-dividend date of this dividend is Monday, June 17th. This represents a $3.08 annualized dividend and a yield of 2.38%. Merck & Co., Inc.’s dividend payout ratio is currently 342.22%.

Analyst Upgrades and Downgrades

Several research analysts have weighed in on MRK shares. Wells Fargo & Company increased their target price on shares of Merck & Co., Inc. from $130.00 to $135.00 and gave the stock an “equal weight” rating in a research note on Wednesday, March 27th. Berenberg Bank raised their price objective on shares of Merck & Co., Inc. from $140.00 to $143.00 and gave the company a “buy” rating in a research note on Monday, April 8th. TheStreet cut shares of Merck & Co., Inc. from a “b+” rating to a “c+” rating in a report on Monday, March 4th. Truist Financial raised their target price on shares of Merck & Co., Inc. from $142.00 to $143.00 and gave the company a “buy” rating in a report on Friday, April 26th. Finally, Argus raised shares of Merck & Co., Inc. to a “strong-buy” rating in a report on Wednesday, June 5th. One research analyst has rated the stock with a sell rating, three have assigned a hold rating, eight have assigned a buy rating and two have given a strong buy rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $133.00.

Check Out Our Latest Stock Analysis on MRK

Merck & Co., Inc. Company Profile

(Free Report)

Merck & Co, Inc operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes under the Keytruda, Bridion, Adempas, Lagevrio, Belsomra, Simponi, and Januvia brands, as well as vaccine products consisting of preventive pediatric, adolescent, and adult vaccines under the Gardasil/Gardasil 9, ProQuad, M-M-R II, Varivax, RotaTeq, Live Oral, Vaxneuvance, Pneumovax 23, and Vaqta names.

See Also

Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRKFree Report).

Institutional Ownership by Quarter for Merck & Co., Inc. (NYSE:MRK)

Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.